|
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Clinical research trials and Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma. Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma clinical trial. Test subjects typically receive the most effective healthcare possible for their Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma  Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
For Condition: recurrent adult diffuse large cell lymphoma
Status: Suspended
Sponsor(s): Jonsson Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial to study the effectiveness of epratuzumab in treating patients who have non-Hodgkin's lymphoma.
Details: OBJECTIVES: - Determine the response rate of patients with diffuse large B-cell non-Hodgkin's lymphoma treated with epratuzumab. - Determine the toxicity of this drug in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment arms. - Arm I: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 4 weeks. - Arm II: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 8 weeks. - Arm III: Patients receive high-dose epratuzumab IV over 1 hour once weekly for 4 weeks. Patients are followed every 3 months for 2 years and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 150 patients (50 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma (NHL) - Relapsed or refractory after at least 1 regimen of standard therapy - Prior therapy may include high-dose chemotherapy with autologous stem cell transplantation (ASCT) or immunotherapy - Bidimensionally measurable disease - At least 1 lesion at least 1.5 cm by CT scan - No primary or secondary CNS lymphoma - No HIV-related lymphoma - No known or suspected transformed lymphoma (prior or concurrent) - No bulky disease (i.e., any single mass greater than 10.0 cm) - No pleural effusion with positive cytology for lymphoma - Most recent pathology specimen available for collection - No rapid disease progression or symptoms that indicate disease progression requiring rapid intervention within the past 2 weeks (e.g., severe shortness of breath, severe pain, or gastrointestinal or genitourinary obstruction) PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 4 months Hematopoietic - Absolute neutrophil count at least 1,000/mm3 - Platelet count at least 50,000/mm3 (transfusion independent) - Hemoglobin at least 9.0 g/dL Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN) - AST and ALT less than 5 times ULN - Hepatitis B surface antigen negative - Hepatitis C negative Renal - Creatinine no greater than 2 times ULN Other - HIV negative - No other primary malignancy within the past 3 years except squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or stage I prostate cancer - No other serious nonmalignant condition that would preclude study - No serious infection - No known human antichimeric antibodies or human antihuman antibody positivity - No type 1 hypersensitivity or anaphylactic reactions to murine proteins - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 6 months after study PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - At least 4 weeks since prior immunotherapy (unless clearly progressing) - At least 12 weeks since prior ASCT Chemotherapy - See Disease Characteristics - At least 4 weeks since prior chemotherapy (unless clearly progressing) Endocrine therapy - Not specified Radiotherapy - No prior radioimmunotherapy Surgery - At least 4 weeks since prior major surgery (unless patient has fully recovered) Other - At least 30 days since prior enrollment in clinical trials involving investigational devices or drugs - No concurrent enrollment in other clinical trials involving investigational devices or drugs - No concurrent investigational agents for disease other than NHL
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ChristosEmmanouilides, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000069484; NCI-G02-2094,UCLA-0201056,AMGEN-AMG-412-159
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00042913
Other Recurrent Adult Diffuse Large Cell Lymphoma Studies:
1. Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
2. Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
3. Chemotherapy and Peripheral Stem Cell Transplantation With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
4. MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
5. Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma
Related Studies:
Other recurrent adult diffuse large cell lymphoma Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
|
|
|
|
|
|
|
|
